Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Sengenics-CancerMed

More Like This

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

PR Newswire associated0

Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Proteintech Genomics' MultiPro™ Human Fixed Cell Immune Profiling Antibody Cocktail containing 53 antibodies against intracellular and cell surface proteins, plus 5 isotype controls (Photo: Business Wire)

Proteintech Genomics Launches First Commercially Available Solution for the Detection of Intracellular Proteins for Single-Cell RNAseq Experiments

Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study

PR Newswire associated0

MGI: Closing the Cancer Care Gap with the Power of Precision Oncology

ACCESSWIRE associated0

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg